RE-BVS – Piemonte Repository

Sfoglia per AUTORE
CASCINU S
Collezione AOU Novara

Items : 7

Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. in Cancer medicine / Cancer Med. 2025 Feb;14(3):e70364. doi: 10.1002/cam4.70364.

2025
AO Ordine Mauriziano
AOU Novara

Bencardino K; Forti L; Spallanzani A; Paratore C; Bernardini I; Giommoni E; Mosconi S; Scartozzi M; Rodriquenz MG; Rapposelli IG; Niger M; Bittoni A; Palloni A; Carloni R; Bergamo F; Chiaravalli M; Gaule M; Cavaliere A; Macchini M; Giordano G; Vasile E; Garajova I; Bozzarelli S; Noventa S; Procaccio L; Salvatore L; di Marco M; Orsi G; Milella M; et alii...

Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). in British journal of cancer / Br J Cancer. 2023 Mar;128(5):877-885. doi: 10.1038/s41416-022-02086-w. Epub 2022 Dec 8.

2023
AO Ordine Mauriziano
AOU Novara

Reni M; Cascinu S; Milella M; Forti L; Valente MM; Bernardino K; Tamburini E; Bernardini I; Niger M; Giommoni E; Peretti U; Spallanzani A; Paratore C; Procaccio L; Salvatore L; Bittoni A; Merelli B; Garajova I; De Lorenzo S; Rapposelli IG; Militello AM; Rodriquenz MG; Bozzarelli S; Noventa S; Scartozzi M; Vasile E; Di Marco M; Giordano G; Macchini M; et alii...

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. in ESMO open / ESMO Open. 2022 Dec;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Epub 2022 Oct 6.

2022
AOU Novara

Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; et alii...

Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. in ESMO open / ESMO Open. 2021 Oct;6(5):100238. doi: 10.1016/j.esmoop.2021.100238. Epub 2021 Aug 13.

2021
AO Ordine Mauriziano
AOU Novara

Reni M; Milella M; Cascinu S; Militello AM; Valente MM; Forti L; Scartozzi M; Giommoni E; Macchini M; Tamburini E; Bencardino K; Mosconi S; Spallanzani A; Paratore C; Bernardini I; Peretti U; Penzo E; De Lorenzo S; Rodriquenz MG; Bittoni A; Garajova I; Tortora G; Rapposelli IG; Giordano G; Noventa S; Bozzarelli S; Niger M; Cavaliere A; Di Marco M; et alii...

Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. in ESMO open / ESMO Open. 2021 Feb;6(1):100032. doi: 10.1016/j.esmoop.2020.100032. Epub 2021 Jan 4.

2021
AO Ordine Mauriziano
AOU Novara

Reni M; Milella M; Cascinu S; Falconi M; Chiarazzo C; De Lorenzo S; De Braud F; Salvatore L; Melisi D; Simbolo M; Calzavara S; Carrera P; Macchini M; Gaule M; Valente MM; Orsi G; Paratore C; Forti LG; Ratti M; Avallone A; Stuppia L; Giordano G; De Vita F; Rapposelli IG; Centonze F; Rodriquenz MG; Di Marco MC; Niger M; Tortora G; et alii...

Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. in Cancer treatment reviews / Cancer Treat Rev. 2020 Jun;86:102020. doi: 10.1016/j.ctrv.2020.102020. Epub 2020 Apr 4.

2020
AOU Novara

Khan K; Cascinu S; Cunningham D; Kim SY; Oki E; Seery T; Shen L; Siena S; Tournigand C; Turhal NS; Hendlisz A;

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. in The Journal of urology / J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18.

2015
AOU Novara

Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; et alii...